Harmen Beurmanjer

54 Chapter 4 records were examined for treatment outcome. The last clinical observation was carried forward in this case. Procedure Patients were informed about the study before admission to the clinic (before detoxification). After informed consent forms were signed, the demographic data, the MATE and the MoCA 7.1 were collected by a trained nurse or psychologist prior to detoxification (T1). After detoxification, on average 20.1 days later, the MoCA 7.2 was administered (T2). Three months after detoxification patients were contacted to assess relapse into GHB use (T3). Data collection occurred between January 2014 and May 2015. Analysis The patient characteristics for age, sex, substance use, MoCA scores (domain, total and cut-off) were summarized using descriptive statistics for both T1 and T2. Differences between the MoCA scores T1 and T2 were analysed using repeated measures ANOVAs for all domain scores and the total score, and Chi² test for categorical variables. Only patients with data available for both time-points were included in these analyses. For each patient a total GHB exposure score was calculated by taking ‘the average daily dose of GHB’ times ‘the number of days GHB was used in the past thirty days’ times ‘the months of daily GHB use’. To study the relationship between MoCA scores (total scores), the number of comas and GHB use (dose per day, months of use, months of daily use, and GHB exposure score) Pearson and Spearman correlations were used where appropriate. The difference on MoCA scores (total score and domain scores) between relapsed and abstinent patients at the three-month follow-up was analysed using MANOVA. In order to assess the predictive value of the MoCA, a backward logistic regression was performed with relapse as the dependent variable and MoCA scores as the independent variables. P-values <0.05 (two-sided) were considered statistically significant. Data were analysed with SPSS Statistics 26. Results Patient characteristics Data of 103 patients were analysed in this study, including 80 MoCA measurements at T1 and 62 at T2. In total 39 patients had completed MoCA measurements at both T1 and T2. These 39 patients did not differ from patients with a MoCA on either T1 or T2 for sex, age, GHB dose, length of daily GHB use, number of comas and MoCA scores. Their mean age was 28.5 years (SD: 6.47) and 68% were men. The mean duration of daily GHB use was 3 1.3 months (SD: 32.61), with a mean of 89.9 ml GHB per day (SD: 52.60). GHB-induced comas